Abstract:OBJECTIVE:To synthesize two antigens-Ag85b and HspX of Mycobacterium tuberculosis H37Rv with molecular biological methods and to observe their biologic activity after co-administration of adjuvants (aluminum and/or CpG) in mice.METHODS:Recombinant expression plasmids pET30a-Ag85b and pET30a-HspX were constructed. The objective DNA fragments was characterized with restriction enzyme. Then the recombinant plasmids were transformed into E. coli BL-21, and two proteins were expressed by induction of isopropyl beta-D-1-thiogalactopyranoside. After purification with anion exchange column Source30, QHP, and hydrophobic chromatography column, two proteins were identified by amino acid sequencing. After the successful preparation of these two antigens, they were co-administered in mice with adjuvants of aluminum and/or CpG (Ag85b, Ag85b + Al, Ag85b + CpG, Ag85b + Al + CpG; HspX, HspX + Al, HspX + CpG, HspX + Al + CpG); one group received normal saline and served as the control. Splenic lymphocytes were isolated for enzyme-linked immunosorbent spot assay to detect the secreted specific interferon-gamma (IFN-gamma); in addition, lymphocytes proliferation test was performed to observe lymphocytes proliferation after in vitro stimulated with two antigens.RESULTS:The purity of two proteins reached 95% after purification. The N-terminal amino acid sequence (15 aa) of the purified proteins was same as the target sequence. For Ag85b, the secreted specific IFN-gamma from isolated splenic lymphocytes after having been stimulated in vitro with Ag85b (80 microg/ml) remarkably increased in Ag85b + CpG group, Ag85b + Al group, and Ag85b + CpG + Al group; the changes were significantly different between these three groups and control group (P < 0.05). For HspX, the changes were significantly different between HspX + Al + CpG group and normal sodium group, although remarked increase of IFN-gamma was also observed in HspX group, HspX + Al group, and HspX + CpG group.CONCLUSIONS:Ag85b and HspX were successfully expressed and purified. A cell-mediated immunity may be induced when the antigens are co-administered with adjuvants of aluminum and/or CpG in mice, indicating that the recombinant proteins are bioactive.

Use of protective antigen of Bacillus anthracis as a model recombinant antigen to evaluate toll-like receptors 2, 3, 4, 7 and 9 agonists in mice using established functional antibody assays, antigen-specific antibody assays and cellular assays

Cpg7909 Adjuvant Enhanced Immunogenicity Efficacy In Mice Immunized With Esat6-Ag85a Fusion Protein, But Does Not Confer Significant Protection Against Mycobacterium Tuberculosis Infection

Aerosolized Intratracheal Inoculation of Recombinant Protective Antigen (rPA) Vaccine Provides Protection Against Inhalational Anthrax in B10.D2-Hc0 Mice

Immune Activation Profiles Elicited by Distinct, Repeated TLR Agonist Infusions in Rhesus Macaques

Protective effect of TLR2/TLR9 agonists on pulmonary Acinetobacter baumannii infection in mice

Bacillus subtilis spore vaccines displaying protective antigen induce functional antibodies and protective potency

Preparation of Two Antigens - Ag85b and HspX of Mycobacterium Tuberculosis H37Rv and the Effects of Their Co-administration with Adjuvants in Mice

TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes

Toll-like Receptor Ligands Differentially Activate Human Innate Immune System and Distinctively Enhance Antigen-Specific T Cell Response to Vaccination in Humanized Mice (VAC4P.1105)

Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine.

Cellular Recognition of Trimyristoylated Peptide or Enterobacterial Lipopolysaccharide Via Both TLR2 and TLR4*

The Msha Strain Of Pseudomonas Aeruginosa Activated Tlr Pathway And Enhanced Hiv-1 Dna Vaccine Immunoreactivity

A recombinant chimeric protein of protective antigen and lethal factor from Bacillus anthracis in polymeric nanocapsules showed a strong immune response in mice: a potential high efficacy vaccine against anthrax

Human Monoclonal Anti-Protective Antigen Antibody for the Low-Dose Post-Exposure Prophylaxis and Treatment of Anthrax

BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models

In Vitro and in Vivo Activities of Recombinant Anthrax Protective Antigen Co-Expressed with Thioredoxin in Escherichia Coli

Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine

A Combination of Small Protein a (smpa) and Phospholipase D (PLD) Immunization Plays a Protective Role in Mice Pneumonia Model of Acinetobacter Baumannii Infection

Different Mechanisms of Two Anti-Anthrax Protective Antigen Antibodies and Function Comparison Between Them

Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice

The Development and Preliminary Evaluation of a Newmycobacterium Tuberculosisvaccine Comprising Ag85b, HspX and CFP-10:ESAT-6 Fusion Protein with CpG DNA and Aluminum Hydroxide Adjuvants